Publications
5674 Results
- Journal / Conference
- American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1400I
Infiltration and spatial distribution of immune cells are associated clinical benefit from Nivolumab/Ipilimumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer: an immune biomarker analysis of Phase III SWOG Lung-MAP S1400I trial
- Journal / Conference
- American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1400I
Immune Gene Expression Signatures associated clinical benefit from Nivolumab/Ipilimumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer: an immune biomarker analysis of Phase III SWOG Lung-MAP S1400I trial
- Journal / Conference
- American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), plenary, oral
- Year
- 2022
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1616
SWOG S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy
- Journal / Conference
- ASCO Gastrointestinal Cancer Symposium (Jan 20-22, 2022, San Francisco, CA), poster session, Abst #193
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Circulating tumor DNA dynamics on front line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: a biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 6; abstr TPS194); ASCO Genitourinary (GU) Cancers Symposium 2022 (Feb 17-19, 2022, San Francisco, CA)
- Year
- 2022
- Research Committee(s)
- Genitourinary
Alliance A031902 (CASPAR): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)
- Journal / Conference
- BMC Urology Mar 26;22(1):45. doi: 10.1186/s12894-022-00986-w.
- Year
- 2022
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID35351104
- PMC
- PMC8966358
- Study Number(s)
- S0000
Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials
- Journal / Conference
- JCO Oncology Practice Jun;18(6):e958-e965
- Year
- 2022
- PMID
- PMID35239419
- PMC
- PMC9191302
Survey of US Medical Oncologists’ Practices and Beliefs regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy
- Journal / Conference
- JAMA Oncology Apr 1;8(4):1
- Year
- 2022
- Research Committee(s)
- Lung
- PMID
- PMID35142793
- Study Number(s)
- S1400I
Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply
- Journal / Conference
- Cancer Epidemiology Biomarkers & Prevention Mar 10;cebp.EPI-21-1008-E.2021. doi: 10.1158/1055-9965.EPI-21-1008. Online ahead of print
- Year
- 2022
- Research Committee(s)
- Cancer Control, Prevention, Screening, and and Surveillance
- PMID
- PMID35266989
- PMC
- PMC9354799
- Study Number(s)
- S0000, SWOG-9217
Large-scale integrated analysis of genetics and metabolomic data reveals potential links between lipids and colorectal cancer risk
- Journal / Conference
- Cancers Apr 14;14(8):1981
- Year
- 2022
- Research Committee(s)
- Cancer Control, Prevention, Screening, and and Surveillance
- PMID
- PMID35454886
- PMC
- PMC9024489
- Study Number(s)
- S0000, SWOG-9217